Preterm Birth and Biomarkers for Cardiovascular Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Preterm Birth
- Sponsor
- Uppsala University
- Enrollment
- 65
- Locations
- 1
- Primary Endpoint
- Levels of Factor XII in plasma in women with preterm birth in compared to a control group with delivery in normal time.
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
Preterm birth is associated with maternal increased risk of cardiovascular disease later in life. In an observational case- control study, investigators want to evaluate whether women with preterm birth have increased levels of biomarkers for cardiovascular disease, to reveal potential pathophysiological mechanisms in common.
Detailed Description
Women with spontaneous preterm birth in first pregnancy and a group of matched controls with spontaneous birth in normal time where invited to participate in the study. Participants were identified from the Biobank of Pregnant Women in Uppsala. Levels of cardiovascular biomarkers will be analyzed in plasma samples from the pregnancy and at a follow-up visit where investigators also collect information about other cardiovascular risk factors and lipid status.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women identified as cases or controls
Exclusion Criteria
- •System inflammatory disease
- •Smoking at the time of the pregnancy
Outcomes
Primary Outcomes
Levels of Factor XII in plasma in women with preterm birth in compared to a control group with delivery in normal time.
Time Frame: spring 2023
Levels of Factor XII in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected.
Levels of complement C5 in women with preterm birth in compared to a control group with delivery in normal time.
Time Frame: spring 2023
Levels of complement C5 in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected.
Levels of apolipoprotein M in women with preterm birth in compared to a control group with delivery in normal time.
Time Frame: spring 2023
Levels of apolipoprotein M in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected.
Levels of vitamin D binding protein in women with preterm birth in compared to a control group with delivery in normal time.
Time Frame: spring 2023
Levels of vitamin D binding protein in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected.
Levels of plasma kallikrein in women with preterm birth in compared to a control group with delivery in normal time.
Time Frame: spring 2023
Levels of plasma kallikrein in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected.
Levels of fibrinogen in women with preterm birth in compared to a control group with delivery in normal time.
Time Frame: spring 2023
Levels of fibrinogen in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected.
Levels of cadherin -5 in women with preterm birth in compared to a control group with delivery in normal time.
Time Frame: spring 2023
Levels of cadherin -5 in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected.
Levels of growth/differentiation Factor-15 (GDF-15) in women with preterm birth in compared to a control group with delivery in normal time. preterm birth compared to a control group with delivery in normal time.
Time Frame: spring 2023
Levels of growth/differentiation Factor-15 (GDF-15) in plasma will be analyzed at two times, both in the actual pregnancy and at a follow-up visit where information about cardiovascular risk factors and lipid status is collected.